Skip to main content
    C

    Celcuity LLC (CELC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $60.57
    -3.80 (-5.90%)

    Market Cap: $3.15B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Celcuity LLC (CELC) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Celcuity LLC (CELC) is expected to report earnings on Mar 23, 2027. In the quarter ended Sep 30, 2026, Celcuity LLC reported EPS of -$1.33, above the -$1.47 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(19/37)
    Avg Surprise
    -7.53%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.41
    Range-$1.86 - -$1.12
    14 analysts
    Revenue Consensus
    $13.87M
    Range$6.37M - $21.00M
    13 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.08
    Range-$1.08 - -$1.08
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.89-21.3%
    60d ago-$0.93-16.1%
    30d ago-$0.93-16.1%
    7d ago-$0.93-16.1%
    Current-$1.08
    Revenue Consensus
    $31.89M
    Range$17.60M - $40.00M
    6 analysts

    Next Report

    CELC has an expected report date of Mar 23, 2027.

    CELC Earnings Call

    The latest CELC earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, CELC beat 19, missed 17 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2021, when EPS landed 214.29% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$1.33-$1.47-$1.60 - -$1.47+9.52%BeatN/A20 up, 2 downNov 5, 2026
    Jun 30, 2026-$1.44-$1.08-$1.25 - -$0.91-33.33%MissN/A20 up, 1 downAug 13, 2026
    Mar 31, 2026-$0.86-$0.89-$0.89 - -$0.89+3.37%BeatN/A11 up, 0 downMay 14, 2026
    Dec 31, 2025-$0.73-$1.05N/A+30.48%BeatN/A30 up, 2 downMar 25, 2026
    Sep 30, 2025-$0.78-$0.96-$0.97 - -$0.94+18.75%BeatN/A30 up, 2 downNov 12, 2025
    Jun 30, 2025-$0.93-$0.84-$0.86 - -$0.83-10.71%MissN/A20 up, 1 downAug 14, 2025
    Mar 31, 2025-$0.81-$0.86-$0.86 - -$0.86+5.81%BeatN/A10 up, 1 downMay 14, 2025
    Dec 31, 2024-$0.75-$0.67-$0.67 - -$0.67-11.94%MissN/A11 up, 0 downMar 31, 2025
    Sep 30, 2024-$0.65-$0.70-$0.70 - -$0.70+7.14%BeatN/A10 up, 1 downNov 14, 2024
    Jun 30, 2024-$0.58-$0.55N/A-5.45%MissN/A70 up, 0 downAug 14, 2024
    Mar 31, 2024-$0.64-$0.71-$0.78 - -$0.59+9.86%BeatN/A60 up, 0 downMay 15, 2024
    Dec 31, 2023-$0.61-$0.75-$0.93 - -$0.51+18.67%BeatN/A60 up, 0 downMar 27, 2024
    Sep 30, 2023-$0.78-$0.53N/A-47.17%MissN/A40 up, 0 downNov 13, 2023
    Jun 30, 2023-$0.58-$0.46N/A-26.09%MissN/A40 up, 0 downAug 10, 2023
    Mar 31, 2023-$0.47-$0.43-$0.69 - -$0.33-9.30%MissN/A40 up, 0 downMay 15, 2023
    Dec 31, 2022-$0.69-$0.44-$0.73 - -$0.33-56.82%MissN/A40 up, 0 downMar 23, 2023
    Sep 30, 2022-$0.75-$0.60-$0.68 - -$0.32-25.00%MissN/A40 up, 0 downNov 10, 2022
    Jun 30, 2022-$0.55-$0.48-$0.59 - -$0.34-14.58%MissN/A40 up, 0 downAug 11, 2022
    Mar 31, 2022-$0.53-$0.51-$0.56 - -$0.45-3.92%MissN/A30 up, 0 downMay 16, 2022
    Dec 31, 2021-$0.37-$0.35-$0.41 - -$0.35-5.71%MissN/A4N/AMar 23, 2022
    Sep 30, 2021-$0.35-$0.24N/A-45.83%MissN/A5N/ANov 8, 2021
    Jun 30, 2021-$0.66-$0.21N/A-214.29%MissN/A3N/AAug 9, 2021
    Mar 31, 2021-$0.21-$0.20-$0.20 - -$0.20-5.00%MissN/A1N/AMay 10, 2021
    Dec 31, 2020-$0.21-$0.22-$0.22 - -$0.22+4.55%BeatN/A1N/AFeb 16, 2021
    Sep 30, 2020-$0.24-$0.23-$0.23 - -$0.23-4.35%MissN/A1N/ANov 9, 2020
    Jun 30, 2020-$0.17-$0.18-$0.18 - -$0.18+5.56%BeatN/A1N/AAug 10, 2020
    Mar 31, 2020-$0.17-$0.17-$0.17 - -$0.170.00%In lineN/A1N/AMay 7, 2020
    Dec 31, 2019-$0.14-$0.18-$0.19 - -$0.18+22.22%BeatN/A2N/AMar 12, 2020
    Sep 30, 2019-$0.16-$0.17-$0.18 - -$0.17+5.88%BeatN/A2N/ANov 7, 2019
    Jun 30, 2019-$0.15-$0.18-$0.20 - -$0.18+16.67%BeatN/A2N/AAug 8, 2019
    Mar 31, 2019-$0.16-$0.20N/A+20.00%BeatN/A2N/AMay 7, 2019
    Dec 31, 2018-$0.15-$0.18-$0.20 - -$0.17+16.67%BeatN/A2N/AFeb 26, 2019
    Sep 30, 2018-$0.15-$0.18N/A+16.67%BeatN/AN/AN/ANov 13, 2018
    Jun 30, 2018-$0.15-$0.17-$0.17 - -$0.17+11.76%BeatN/A1N/AAug 9, 2018
    Mar 31, 2018-$0.16-$0.19-$0.19 - -$0.19+15.79%BeatN/A1N/AMay 14, 2018
    Dec 31, 2017-$0.14-$0.15-$0.15 - -$0.15+6.67%BeatN/A1N/AMar 15, 2018
    Sep 30, 2017-$0.20-$0.19N/A-5.26%MissN/AN/AN/ANov 13, 2017
    Jun 30, 2017-$0.11N/AN/AN/AN/AN/AN/AN/ASep 20, 2017
    Last 38 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.25, after -$2.62 the year before. It was -$0.45 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.25N/A
    Dec 31, 2024-$2.62N/A
    Dec 31, 2023-$2.44N/A
    Dec 31, 2022-$2.52N/A
    Dec 31, 2021-$1.59N/A
    Dec 31, 2020-$0.79N/A
    Dec 31, 2019-$0.61N/A
    Dec 31, 2018-$0.61N/A
    Dec 31, 2017-$0.45N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,500 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,53315
    2026Q2Jun 30, 20265,22414
    2026Q1Mar 31, 20265,63315
    2025Q4Dec 31, 20255,21313
    2025Q3Sep 30, 20253,70711
    2025Q2Jun 30, 20254,47710
    2025Q1Mar 31, 20253,7059
    2024Q4Dec 31, 20245,54710

    2026Q3 Earnings Call

    Opening remarks

    Jodi Sievers Investor Relations Thank you, Marissa, and good afternoon, everyone. Thank you for joining us to review Celcuity's third quarter 2026 financial results and business update. Earlier today, Celcuity, Inc. released financial results for the quarter ended September 30, 2026. The press release can be found on the Investors section of Celcuity's website. Joining me on the call today are Brian F. Sullivan, Celcuity's Chief Executive Officer and co-founder; Vicky Hahne, our Chief Financial Officer; as well as Igor, our Chief Medical Officer, and Eldon C. Mayer, our Chief Commercial Officer, who will both be available for questions during Q&A. Before we begin, I would like to remind listeners that our comments today include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today's press release and in our reports and filings with the SEC. Actual events or results may differ materially from those projected in forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. On this call, we also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results, and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table reconciling the non-GAAP financial measures to GAAP measures in today's press release. With that, I would like to turn the call over to Brian F. Sullivan, CEO of Celcuity.

    Brian F. Sullivan CEO Thank you, Jodi, and good afternoon, everyone. Thank you for joining our third quarter 2026 operating and financial update conference call. 2026 has been a transformative year for Celcuity as we transition to a commercial-stage company. Revtopik is now available to U.S. physicians to prescribe for use in combination with fulvestrant, with or without palbociclib, for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The unprecedented efficacy results and favorable safety profile reported from the PIK3CA wild-type cohort of the VIKTORIA-1 study provide physicians with a compelling rationale to utilize a gedatolisib regimen to address a significant unmet need for the tens of thousands of patients affected each year by advanced breast cancer. We are pleased to report and provide our first update on the results of the foundational work our commercial and medical teams have been performing for the past two years to prepare for the commercial launch of Revtopik.

    Frequently Asked Questions About CELC

    When is Celcuity LLC's next earnings date?

    Celcuity LLC's next earnings report is expected for Mar 23, 2027.

    Did CELC beat earnings estimates last quarter?

    Yes. Celcuity LLC reported EPS of -$1.33 for the quarter ended Sep 30, 2026, above the -$1.47 estimate, a 9.52% surprise.

    What EPS do analysts expect from CELC next quarter?

    The consensus EPS estimate for Celcuity LLC for the quarter ending Dec 31, 2026 is -$1.41 from 14 analysts, with estimates from -$1.86 to -$1.12.

    How often does CELC beat earnings estimates?

    Celcuity LLC beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +1.49%.